Bioventus Inc., a medical device company, focuses on developing and commercializing clinical treatments that involve and enhance the body's natural healing process in the United States and internationally. The company is headquartered in Durham, North Carolina.
| Revenue (TTM) | $576.30M |
| Gross Profit (TTM) | $395.87M |
| EBITDA | $80.90M |
| Operating Margin | 6.73% |
| Return on Equity | 16.50% |
| Return on Assets | 5.61% |
| Revenue/Share (TTM) | $8.61 |
| Book Value | $2.79 |
| Price-to-Book | 4.47 |
| Price-to-Sales (TTM) | 1.55 |
| EV/Revenue | 1.875 |
| EV/EBITDA | 10.46 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 6.60% |
| Shares Outstanding | $67.75M |
| Float | $33.31M |
| % Insiders | 11.75% |
| % Institutions | 78.32% |
Volatility is currently contracting
Bioventus (BVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DURHAM, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market opens on Wednesday, August 5, 2026.
Here is how Bioventus (BVS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
The consensus price target hints at a 28.9% upside potential for Bioventus (BVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Does Bioventus (BVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
The mean of analysts' price targets for Bioventus (BVS) points to a 28.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Bioventus Inc. develops medical devices and biologics for orthopedic recovery and pain relief. I previously rated it a 'Hold' due to debt, competition, weak cash flow, and valuation concerns despite strong Q2 2024 growth. BVS has recently outperformed the S&P 500 and medtech ETFs, with a breakout driven by favorable regulatory developments.
Bioventus (BVS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BVS and any ticker you trade — then tracks every position and per-strategy win rate.
